Venture Capital · Profile from Venture Capital Research Companion
ARCH Venture Partners
The University of Chicago spin-out that evolved from a tiny tech-transfer fund into biotech's most aggressive company-creation machine — known for founding companies around academic science and capitalising them with $100m-to-$1bn+ "mega-launches" that few rivals can match.
At a glance
- Founded
- 1986 as the venture arm of the ARCH (Argonne–Chicago) Development Corporation; first fund ~1988–89; independent partnership from ~1992–93
- Founders
- Steven Lazarus (head of ARCH Development Corp), with Robert (Bob) Nelsen, Keith Crandell and, slightly later, Clinton Bybee — Chicago Booth graduate students known as the "57th Street Irregulars"
- Headquarters
- Chicago, IL (historic HQ); major presence in Seattle (Nelsen) and the San Francisco Bay Area; smaller offices over time in Austin, Albuquerque/Santa Fe, New York and elsewhere
- Ownership / structure
- Private partnership owned by its managing directors; originally wholly owned by the University of Chicago, which exited around the second fund
- Leadership (2026)
- Co-founders Robert Nelsen and Keith Crandell remain managing directors; other senior MDs include Kristina Burow and Steven Gillis (Immunex co-founder) and Paul Berns (verify current roster)
- AUM / capital raised
- ~$9bn+ cumulative commitments reported by 2022; with Fund XIII (>$3bn, 2024) cumulative capital raised is roughly $12–13bn+ (estimate; firm does not publish a single AUM figure)
- Stage focus
- Seed and company creation through Series A/B, with heavy follow-on and crossover participation via "overage" vehicles; overwhelmingly biotech/life sciences since ~2010, historically also physical sciences, semiconductors, nanotech and IT
- Signature investments
- Illumina, Alnylam (firm-cited early investor), Kythera, Receptos, Juno Therapeutics, Denali, GRAIL, Vir Biotechnology, Sana, Lyell, Xaira; failures/disappointments: Nanosys (pulled 2004 IPO), Unity Biotechnology (dissolution 2025), large post-IPO drawdowns at Sana and Lyell
10 deals and moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1998
Illumina
Early Venture Financing
2001
Nanosys
Series A / Early Venture
2011
Unity Biotechnology
Seed / Company Creation
2013
Juno Therapeutics
Series A
2015
Denali Therapeutics
Series A
2016
GRAIL
Series A
2016
Vir Biotechnology
Series A / Launch
2018
Lyell Immunopharma
Company Creation
2018
Sana Biotechnology
Company Creation
2024
Xaira Therapeutics
Launch Financing